Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG KCP-330-008

Title
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician’s Choice in Patients = 60 Years Old with Relapsed/Refractory Acute Myeloid Leukemia (AML) Who are Ineligible for Intensive Chemotherapy and/or Transplantation
Principal Investigator
Olga Frankfurt
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG KCP-330-008
Purpose
The purpose of this study is to evaluate the effects of KPT-330 in treatment of relapsed/refractory acute myleloid leukemia(AML).
Overview
Relapsed/refractory AML can have limited treatment options. The medical and scientific communities are always looking at promising treatments. The study drug, KPT-330, is an investigational drug. It has not been approved by the U.S. Food & Drug Administration. KPT-330 works by trapping certain proteins in the cell and cause the cancer cells to die or stop growing. KPT-330 has been tested to establish a safe dose. This study will look at what effects, good and/or bad, has on AML and the participants by comparing it to treatment by current standard drugs.
Eligibility
Some of the eligibility criteria include:
  • Participants must be at least 60 years of age or older.
  • Participants must have relapsed(cancer came back)/refractory(cancer does not respond to treatment)acute myeloid leukemia (AML).
  • Participants have not undergone and are not eligible for stem cell transplantation.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
This is a randomized (like the flip of a coin) study. Participants will be assigned to one of two groups, 2/3 of participants will be put into group 1. Group 1 will take KPT-330 orally (by mouth) twice a week. Group 2 will receive one of 3 current standard treatments for AML. The study doctor will decide which one a participant in group 2 will receive. Participants will remain on the study until their disease worsens or the study doctor feels it is in their best interest to stop.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Olga Frankfurt

last updated: 25-Oct-14 12:29 PM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.